Targovax, a Norwegian immune-oncology company, said that its lead candidate ONCOS-102 has secured the fast track designation from the US Food and Drug Administration (FDA) for malignant pleural mesothelioma. The FDA fast track status to ONCOS-102 was granted based on promising pre-clinical and clinical efficacy related to broad immune activation observed so far, said Targovax. […]